Sibutramine warning

From JAMA:

Preliminary data suggest that taking the weight loss drug sibutramine (aka Meridia in the US or Reductil in the UK) may increase a patient’s risk of adverse cardiovascular events such as heart attack and/or stroke, according to the US Food and Drug Administration (FDA).

After reviewing the study, the FDA asked the manufacturer to add a warning to the label. The manufacturer, Knoll Pharmaceutical Company, has agreed to add the warning.